Crossmark

ASO Author Reflections: Is Sentinel Node Biopsy Still of Value for Patients with High-Risk Primary Melanomas Eligible for Adjuvant Immunotherapy?

Published Online: 2024-12-27

Authors

Pennington, Thomas E.

Thompson, John F.

Varey, Alex H. R.
License Information

Text and Data Mining valid from 2024-12-27

Version of Record valid from 2024-12-27
More Information

Article History

Received: 16 December 2024

Accepted: 16 December 2024

First Online: 27 December 2024

Disclosures

: Alex H.R. Varey has received honoraria from Novartis and MSD. Thomas E. Pennington and John F. Thompson have no conflicts of interest to declare that may be relevant to the contents of this study.

Document is current